IFPMA media briefing on COVID-19 response commits to vaccine equity

The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) today held a virtual press briefing with chief executives and top executives who are in the forefront of biopharmaceutical R&D for COVID-19.

They concluded that historic COVID-19 manufacturing scale up should now urgently shift attention to delivering vaccine equity including dose sharing.

In May 2021, the innovative biopharmaceutical industry publicly committed to expend every effort to make additional uncommitted COVID-19 doses available to low- and lower-middle-income countries (LMIC) and to support governments that have significant domestic supplies of COVID-19 vaccine doses to share a meaningful proportion of their doses with LMICs in a responsible and timely way through COVAX or other efficient established mechanisms.